Since 1995, when the first Hsp90 inhibitor was shown to demonstrate antitumor efficacy in mouse xenograft tumor models, there has been considerable effort focused on the development of Hsp90 inhibitors for the treatment of cancer. Here, HSP90AA1 is linked to cancer.